Available Technologies
# of Displayed Technologies: 10 / 63
Applied Category Filter (Click To Remove): Oncology
Noninvasive Rapid Radiation Exposure Assay
TS-068290 — The Need
Radiation exposure poses significant health risks, including cancer and other illnesses, making it crucial for clinicians to accurately measure and assess the extent of radiation exposure. Existing methods often require invasive procedures and may not detect exposure at lower dose ranges.
…
- College: College of Arts & Sciences
- Inventors: Schultz, Zachary; Jacob, Naduparambil; Morder, Courtney; Witte, Spencer
- Licensing Officer: Panic, Ana
Humanized SSTR2 mAb and ADC to target SSTR2+ tumors
TS-066912 — Targeted humanized mAbs and ADCs for cancer treatment
The Liu Lab
Dr. Xiaoguang “Margaret” Liu applies her industry experience (Lonza, Merck, and Life Technologies) in cell line and process development towards her lab’s focus on targeted anti-cancer therapies including monoclonal antibodies, antibody-drug conjugates, and gene therapi…
- College: College of Engineering (COE)
- Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
- Licensing Officer: Schworer, Adam
Small Molecule USP30 Inhibitors for the Treatment and Prevention of Cardiomyopathy
TS-066773 — The Need
Cardiomyopathy, a disease of the heart muscle, poses significant public health challenges due to its diverse causes, symptoms, and potential complications, including heart failure and arrhythmias. With cardiomyopathy often induced by drugs, such as anthracyclines used in chemotherapy, ther…
- College: College of Medicine (COM)
- Inventors: Sun, Nuo; Krigman, Judith; Yang, Mingchong; Zhang, Ruohan
- Licensing Officer: Willson, Christopher
T-cells with Enhanced Ability to Respond to Exogenous Ligands
TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.
The Need
As interest in cell-based therapies, particularly for cancer treatment, continues to rise, there’s a critical need for therapeutic cells capable of robust proliferation in vivo. Existing methods relying on exogenous cytokines like IL-2 face challenges due to dose-limiting toxicity an…
- College: OSU Wexner Medical Center
- Inventors: Rubinstein, Mark
- Licensing Officer: Willson, Christopher
Novel Antibodies Targeting IL-2
TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.
IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Expression of intermediate-affinity IL-2 receptors by different immune cell subsets determines cellular sensitivity to IL-2. However, the dynamic interplay bet…
- College: OSU Wexner Medical Center
- Inventors:
- Licensing Officer: Willson, Christopher
Revolutionizing Cancer Immunotherapy with Novel Chimeric B-cell Epitope Peptide Vaccines
TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.
The emergence of immune checkpoint inhibitors revolutionized cancer immunotherapy. Monoclonal antibodies targeting PD-1, PD-L1 and CTLA-4 have shown impressive clinical outcomes.
The Need
Despite their effectiveness, current monoclonal antibody treatments have limitations such as low response ra…
- College: College of Medicine (COM)
- Inventors: Kaumaya, Pravin
- Licensing Officer: Willson, Christopher
MicroRNA profile predicts colon cancer prognosis
TS-065453 — The Need:
Colon cancer remains one of the most prevalent and lethal forms of cancer worldwide. Timely and accurate diagnosis is critical for effective treatment and improved patient outcomes. Current diagnostic methods often lack the precision and sensitivity needed for early detection and prognosi…
- College: College of Medicine (COM)
- Inventors: Croce, Carlo
- Licensing Officer: Schultz, Teri
Intracellular Targeting by Monoclonal Antibodies
TS-064581 — Antibodies are essential therapeutic modalities for treating a plethora of different diseases, ranging from cancer, autoimmune disorders, degenerative diseases, and inflammation. The FDA approved the first antibody over three decades ago, and since more than 570 have been studied in clinical trials,…
- College: College of Arts & Sciences
- Inventors: Magliery, Thomas; Do, Jamie; Han, Jeong Min "Mina"; Zhu, Ian
- Licensing Officer: Dahlman, Jason "Jay"
Magnetic Nanoparticles for Cancer Cell Classification
TS-064577 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately only 40% living past the first-year post-diagnosis and 17% in the second year.
The Need
Developing drugs for cance…
- College: College of Arts & Sciences
- Inventors: Schultz, Zachary; Rist, David; Skardal, Aleksander; Venere, Monica
- Licensing Officer: Panic, Ana
Utilizing WT-IV-012 to improve immune checkpoint therapy in cancer treatment
TS-064262 — The Need
Addressing the limitations of current melanoma therapies, there exists a critical need for innovative approaches that enhance the effectiveness of immune checkpoint therapeutics. Despite advancements in immunotherapy, a significant percentage of melanoma patients do not achieve complete re…
- College: College of Arts & Sciences
- Inventors: Burd, Craig; Aguilar-Valenzuela, Renan; Burd, Christin
- Licensing Officer: Panic, Ana
